Exyn Technologies' Interim CEO Ben Williams will appear on Cheddar News to discuss the company's ExynAI technology, which enables drones and robots to navigate without GPS in complex environments. The technology has applications in defense, mining, and critical infrastructure, including a U.S. Department of Energy project for autonomous mineral discovery. This highlights Exyn's expanding role in mission-critical sectors and potential growth opportunities.
Exyn Technologies' Interim CEO Ben Williams is featured in this update. For readers following the Technology sector, here is Pluang's market snapshot as of Nov 02, 2026 20:11 WIB: out of 150 priced US stocks, 106 rose and 32 fell today. Notable movers include Applovin Corporation (APP) at USD 234.71 with a 1-day change of +2.72%, Unity Software Inc (U) at USD 38.64 with +2.49%, and Teradyne, Inc. (TER) at USD 280.95 with +2.40%.
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
